Article
Carrie Printz
Expanding the Reach of TIL Therapy: What Will it Take?
Clips
Summary
Dr. Mahuron shares how tumor-infiltrating lymphocyte (TIL) therapy is evolving to reach more patients and improve cancer outcomes.
What does it take to bring tumor-infiltrating lymphocyte (TIL) therapy to more patients and make the therapy more effective for those already eligible?
In this episode of Edge of Breakthrough, Dr. Monty Pal sits down with Dr. Kelly Mahuron, a surgical oncologist at City of Hope, to unpack how TIL therapy is evolving. From identifying eligible patients and surgical harvesting of TILs to cell expansion and reinfusion, Dr. Mahuron breaks down the entire process of TIL therapy, highlighting how her cross-disciplinary team is working to improve patient outcomes, reduce toxicity, and eventually expand treatment beyond melanoma.
They also explore the next generation of TILs f, and how oncolytic viruses and modified immune environments might bring TILs to more resistant cancers such as pancreatic and colorectal tumors.
Learn how surgical precision, immunotherapy, and translational research come together to push the boundaries of what's possible in cancer treatment. . Tune in to the full conversation now.
Related Topics
You May Also Like
Carrie Printz
Podcast
Monty Pal
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Podcast
Monty Pal
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS